Sort by

Send to:

Choose Destination

Results: 5


Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.

Arnou R, Fiquet A, Thomas S, Sadorge C.

Hum Vaccin. 2011 Oct;7(10):1060-5. doi: 10.4161/hv.7.10.16480. Epub 2011 Oct 1.


Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany.

Arnou R, Frank M, Hagel T, Prébet A.

Adv Ther. 2011 Jul;28(7):555-65. doi: 10.1007/s12325-011-0035-z. Epub 2011 May 20.


Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.

Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E.

BMC Infect Dis. 2010 May 26;10:134. doi: 10.1186/1471-2334-10-134.


Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial.

Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F.

Hum Vaccin. 2010 Apr;6(4):346-54. Epub 2010 Apr 15.


Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P.

Vaccine. 2009 Dec 9;27(52):7304-12. doi: 10.1016/j.vaccine.2009.10.033. Epub 2009 Oct 20.

Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk